A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke

NCT05445895 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 483

Last updated 2025-11-21

No results posted yet for this study

Summary

A study to Evaluate the Efficacy and Safety of Renexin CR in patients with Acute Non-cardioembolic Ischemic Stroke

Conditions

Interventions

DRUG

Renexin CR 200/160mg

Renexin CR 200/160mg will be added to Aspirin 100mg

DRUG

Plavix 75mg

Plavix 75mg will be added to Aspirin 100mg

Sponsors & Collaborators

  • SK Chemicals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-16
Primary Completion
2025-10-02
Completion
2025-11-07

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05445895 on ClinicalTrials.gov